细胞培养基市场 - 按产品类型（无血清培养基 {CHO、HEK 293、BHK}、干细胞培养基）、应用（生物製药生产 {疫苗、单株抗体}、诊断）、最终用户 - 全球预测（2024 - 2032）

细胞培养基市场规模预计从 2024 年到 2032 年将以 12.8% 的复合年增长率扩大。技术的发展，包括 3D 细胞培养和干细胞研究的创新，正在推动对先进培养基配方的需求。

对慢性疾病，特别是癌症的研究不断增加，也刺激了对细胞培养基的需求。根据美国国家癌症研究所的资料，到2024 年，美国将诊断出约2,001,140 例新癌症病例。 。

整个市场分为产品类型、应用、最终用户和地区。

根据产品类型，由于个人化医疗需求不断增加、再生医学和干细胞研究的进步，特种培养基领域的细胞培养基市场预计将在 2024 年至 2032 年间大幅成长。专业配方对于精确的细胞环境以及支持标靶治疗和复杂细胞培养技术的开发至关重要。生物製药研发投资的不断增加以及对高品质、可重复结果的需求不断增长正在推动该领域的成长。

在疾病诊断和个人化医疗不断扩大的研究的带动下，诊断应用领域的细胞培养基产业将从 2024 年到 2032 年以显着的速度成长。细胞培养基在培养患者来源的细胞以进行诊断测试、生物标记发现和药物敏感性测定方面发挥着至关重要的作用。此外，分子诊断的进步和慢性病的日益普及刺激了对适合诊断应用的准确可靠的细胞培养基配方的需求。

从地区来看，由于生物製药产业的扩张，特别是在中国和印度等国家，预计到 2032 年，亚太地区细胞培养基市场将呈现强劲成长。对医疗基础设施和研究设施的投资不断增加。先进细胞培养技术的日益普及以及对个人化医疗的认识不断增强，正在加速产品的部署。政府推出的有利措施以及与国际生物技术公司的合作也正在推动区域市场的发展。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病发生率上升
    • 细胞培养基技术的进步
    • 对无血清和动物成分培养基的需求不断增加
    • 再生医学需求不断成长
  • 产业陷阱与挑战
    • 细胞生物学产品成本高
    • 严格的监管挑战
• 成长潜力分析
• 新兴科技格局
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

• 主要趋势
• 无血清培养基
  • CHO媒体
  • HEK 293 媒体
  • BHK媒体
  • VERO细胞培养基
  • 昆虫细胞培养基
  • 免疫细胞培养基
  • 其他无血清培养基
• 专业媒体
• 化学成分确定的培养基
• 干细胞培养基
• 其他产品类型

第 6 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 生物製药生产
  • 单株抗体
  • 疫苗生产
  • 其他生物製药产品
• 诊断
• 药物筛选与开发
• 组织工程与再生医学
• 研究目的
• 其他应用

第 7 章：市场估计与预测：按最终用户划分，2021 - 2032 年

• 主要趋势
• 製药和生物技术公司
• 医院和诊断实验室
• 研究和学术机构
• 其他最终用户

第 8 章：市场估计与预测：按地区，2021-2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 9 章：公司简介

• ACROBiosystems
• Corning Incorporation
• Danaher Corporation
• FUJIFILM Irvine Scientific
• Lonza Group
• Merck KGaA
• Miltenyi Biotech
• Nuvonis
• Sartorius AG
• ScienCell Research Laboratories
• Thermo Fisher Scientific Inc.

Cell Culture Media Market size is projected to expand at 12.8% CAGR from 2024 to 2032. The rising demand for biopharmaceuticals, such as vaccines and monoclonal antibodies is necessitating the use of high-quality cell culture media in production processes. Technological developments, including the innovations in 3D cell cultures and stem cell research are driving the need for advanced media formulations.

The increasing research on chronic diseases, particularly cancer is also fueling the demand for cell culture media. As per data from the National Cancer Institute, in 2024, around 2,001,140 new cases of cancer will be diagnosed in the U.S. The expanding fields of regenerative medicine and tissue engineering is increasing the funding from government and private sectors for cell-based research, driving the industry growth.

The overall market is segregated into product type, application, end-user, and region.

Based on product type, the cell culture media market from the specialty media segment is estimated to rise at significant rate between 2024 and 2032, due to the increasing demand for personalized medicine, advancements in regenerative medicine, and stem cell research. Specialized formulations are essential for precise cellular environments as well as supporting the development of targeted therapies and complex cell culture techniques. The rising investments in biopharmaceutical R&D and the growing need for high-quality, reproducible results are driving the segment growth.

Cell culture media industry from the diagnostics application segment will grow at notable rate from 2024 to 2032, led by the expanding research in disease diagnostics and personalized medicine. Cell culture media is serving a crucial role in culturing patient-derived cells for diagnostic testing, biomarker discovery, and drug sensitivity assays. Moreover, the advancements in molecular diagnostics and the growing prevalence of chronic diseases are spurring the demand for accurate and reliable cell culture media formulations tailored to diagnostic applications.

Regionally, the Asia Pacific cell culture media market is anticipated to depict robust growth through 2032, owing to the expansion of the biopharmaceutical sector, particularly in countries like China and India. There have been rising investments in healthcare infrastructure and research facilities. The increasing adoption of advanced cell culture technologies, and growing awareness about personalized medicine is accelerating the product deployment. The launch of favorable government initiatives and collaborations with international biotech companies are also driving the regional market progression.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Advancement in cell culture media technology
    • 3.2.1.3 Increasing demand for serum and animal component-free media
    • 3.2.1.4 Growing demand for regenerative medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of cell biology products
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Emerging technology landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company positioning matrix
• 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Serum-free media
  • 5.2.1 CHO media
  • 5.2.2 HEK 293 media
  • 5.2.3 BHK media
  • 5.2.4 VERO cell media
  • 5.2.5 Insect cell media
  • 5.2.6 Immune cell media
  • 5.2.7 Other serum-free media
• 5.3 Specialty media
• 5.4 Chemically defined media
• 5.5 Stem cell culture media
• 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Biopharmaceutical production
  • 6.2.1 Monoclonal antibodies
  • 6.2.2 Vaccine production
  • 6.2.3 Other biopharmaceutical productions
• 6.3 Diagnostics
• 6.4 Drug screening and development
• 6.5 Tissue engineering and regenerative medicine
• 6.6 Research purpose
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Hospital and diagnostic laboratories
• 7.4 Research and academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021- 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 ACROBiosystems
• 9.2 Corning Incorporation
• 9.3 Danaher Corporation
• 9.4 FUJIFILM Irvine Scientific
• 9.5 Lonza Group
• 9.6 Merck KGaA
• 9.7 Miltenyi Biotech
• 9.8 Nuvonis
• 9.9 Sartorius AG
• 9.10 ScienCell Research Laboratories
• 9.11 Thermo Fisher Scientific Inc.